Premium
Epigenetic regulation of soluble guanylate cyclase (sGC) β1 in breast cancer cells
Author(s) -
Sotolongo Alex,
Zakia Mónica Fabiola,
Kots Alex,
Xiao Haijie,
Liu Jun,
Seto Edward,
Bian Ka,
Murad Ferid
Publication year - 2016
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.201600339r
Subject(s) - hdac3 , soluble guanylyl cyclase , epigenetics , cancer research , chromatin immunoprecipitation , transcription factor , hdac1 , microbiology and biotechnology , histone deacetylase , biology , medicine , promoter , chemistry , histone , gene expression , receptor , gene , guanylate cyclase , biochemistry
Soluble guanylate cyclase (sGC) is a heterodimer composed of a and b subunits. The loss of sGCβ1 has been implicated in several vascular and nonvascular diseases. Our analysis showed that higher levels of sGCβ1 in breast cancer tissues are correlated with greater survival probability than lower sGCβ1 levels. However, there is no information on sGC regulation by epigenetic mechanisms. We examined the role of histone deacetylase (HDAC) inhibitors in regulating sGCα1and ‐β1 expression in human breast cancer MDA‐MB‐231 and MDA‐MB‐468 cell lines. The class I HDAC inhibitors increased the expression of sGCβ1more thansGCα1. Transient overexpression of HDAC3, but not HDAC1 or HDAC2, significantly reduced sGCβ1 mRNA. Chromatin immunoprecipitation assay confirmed an enhanced binding of HDAC3 to the sGCβ1 proximal promoter, which could be reversed by panobinostat (LBH‐589) treatment. Mutations at the CCAAT binding sequence, a major element regulating sGCβ1 expression, markedly reduced the efficacy of LBH‐589 in augmenting sGCβ1 promoter activity. LBH‐589 markedly enhanced the binding of nuclear transcription factor Y, subunit a, tothe sGCβ1 promoter (CCAAT binding sequence). In summary, HDAC3 is an endogenous antagonist of sGCβ1 expression. Inhibition of HDAC3 with targeted therapy could benefit treatment of the diseases associated with sGCβ1 down‐regulation and/or deficiency such as cancer and several vascular‐related diseases.—Sotolongo, A., Mónica, F. Z., Kots, A., Xiao, H., Liu, J., Seto, E., Bian, K., Murad, F. Epigenetic regulation of soluble guanylate cyclase (sGC) β1 in breast cancer cells. FASEB J. 30, 3171–3180 (2016). www.fasebj.org